internal
David Ricks
Chair, President, and Chief Executive Officer
Executive
9 yr
13 reports
Eli Lilly and Company ·LLY
Seven therapy-area presidents report directly to the CEO
Health Care · Fortune #100 · Divisional structure · 47K employees · Indianapolis, Indiana
View as of:
12
CEO span
↑ wider than peers (avg 8)
1.8
Avg span
tight
3
Max depth
3 levels
2.6 yr
Avg tenure
stable vs FY2024
75%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$65.2B
Net income
$20.6B
Total assets
$112.5B
Shares out
943M
Sourced from Eli Lilly and Company DEF 14A · filed 2026-03-20 ↗ View on SEC
Interactive org chart
Eli Lilly and Company organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Seven therapy-area presidents report directly to the CEO. This page maps Eli Lilly’s divisional executive structure, detailing the CEO’s broad span, centralized R&D, recent leadership changes, and how the model compares with pharma peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Carole Ho joined as EVP and President, Lilly Neuroscience
Appointed January 2025.
Source · See change logScenario views in the chart
- Add Chief Operating Officer Introduce a COO to consolidate manufacturing and commercial operations, reducing CEO span.
- Consolidate Therapy Presidents Group therapy-area presidents under a single Chief Commercial Officer.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
12 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
internal
Daniel M. Skovronsky
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories
R&D
1 yr
0 reports
internal
Lucas Montarce
Executive Vice President and Chief Financial Officer
Finance
2 yr
1 reports
Anat Hakim
Executive Vice President, General Counsel and Secretary
Legal
6 yr
0 reports
internal
Eric Dozier
Executive Vice President, Chief People Officer
Human Resources
4 yr
0 reports
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
IT & Digital
5 yr
0 reports
internal
Edgardo Hernandez
Executive Vice President and President, Manufacturing Operations
Manufacturing
5 yr
0 reports
internal
Patrik Jonsson
Executive Vice President and President, Lilly International
International
1 yr
0 reports
internal
Ilya Yuffa
Executive Vice President and President, Lilly USA and Global Customer Capabilities
Commercial
1 yr
0 reports
internal
Jacob Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
Oncology
1 yr
0 reports
Carole Ho
Executive Vice President and President, Lilly Neuroscience
Neuroscience
1 yr
0 reports
internal
Adrienne Brown
Executive Vice President and President, Lilly Immunology
Immunology
1 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 2 named executive officers disclosed. Bar length scales with total compensation.
David A. Ricks $36.7M
- Base salary
- $1.70M
- Bonus
- $23.32M
- Stock awards
- $6.49M
- Non-equity incentive
- $4.45M
- Pension change
- $736K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Lucas Montarce $8.5M
- Base salary
- $1.00M
- Bonus
- $5.00M
- Stock awards
- $2.18M
- Non-equity incentive
- $243K
- Pension change
- $60K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The skin in the game
Beneficial ownership
Insider stock holdings and the company's ownership requirements for executives and directors. Disclosed in the most recent DEF 14A.
Stock ownership requirements
6×CEO base salary
3×NEO base salary
5×Director cash retainer
Stock ownership guidelines disclosed in proxy.
The businesses
How Eli Lilly and Company divides the work
4 divisions report into the group CEO. Tile size scales with estimated headcount.
Oncology
6K employees
President, Lilly Oncology (Jacob Van Naarden)
Leads global oncology R&D, development, and commercialization.
Neuroscience
5K employees
President, Lilly Neuroscience (Carole Ho)
Focuses on Alzheimer’s and other CNS disorders.
Immunology
4K employees
President, Lilly Immunology (Adrienne Brown)
Develops immunology and inflammation therapies.
Cardiometabolic Health
7K employees
President, Lilly Cardiometabolic Health (Kenneth Custer)
Drives diabetes, obesity, and cardiometabolic portfolio.
The thesis
Why this org is unusual
Seven therapy-area presidents report directly to the CEO, an unusually broad span for a large-cap pharma.
Lilly’s structure emphasizes disease-area accountability—Oncology, Neuroscience, Immunology, Cardiometabolic—alongside enterprise functions. This creates parallel P&L leadership while keeping R&D centralized under a single CSPO. The CEO’s span reflects rapid portfolio expansion and commercialization scale.
- Multiple therapy presidents
- Centralized R&D leadership
- No COO role
The comparison
How Eli Lilly and Company stacks up
Compared with peers like Pfizer and Merck, Lilly runs a more therapy-led executive model, with more presidents reporting directly to the CEO and fewer layers. This contrasts with companies that consolidate commercial units under a COO. The model increases CEO span but accelerates decision-making in priority disease …
C-suite size
Reporting depth
Eli Lilly and Company
3 levels
5 levels
5 levels
Johnson & Johnson
6 levels
5 levels
Novo Nordisk
4 levels
Avg C-suite tenure
Eli Lilly and Company
3 yr
4 yr
5 yr
Johnson & Johnson
4 yr
Novo Nordisk
6 yr
Has COO / Has CAIO
Eli Lilly and Company — no COO — no CAIO
Johnson & Johnson ✓ COO — no CAIO
Novo Nordisk — no COO — no CAIO
Current signals
What changed recently
In 2025 Lilly elevated three therapy-area presidents, expanding the CEO’s direct-report span.
- Date not confirmed new
- Date not confirmed promoted
- Date not confirmed promoted
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-03-20
- CEO
- David Ricks
- CEO span
- 12
- C-suite
- 12
- Avg tenure
- 2.6 yr
Expanded therapy-area leadership.
Named executive officers (5)
- David Ricks - CEO since 2017
- Lucas Montarce - CFO since 2024
- Daniel Skovronsky - CSPO since 2025
- Anat Hakim - General Counsel since 2020
- Jacob Van Naarden - President, Oncology since 2025
FY2024
DEF 14A filed 2025-03-21
- CEO
- David Ricks
- CEO span
- 10
- C-suite
- 10
- Avg tenure
- 3.4 yr
Fewer therapy presidents.
Named executive officers (5)
- David Ricks - CEO since 2017
- Anat Ashkenazi - CFO since 2021
- Daniel Skovronsky - Chief Scientific Officer since 2024
- Anat Hakim - General Counsel since 2020
- Jake Van Naarden - President, Oncology since 2021
FY2023
DEF 14A filed 2024-03-22
- CEO
- David Ricks
- CEO span
- 9
- C-suite
- 9
- Avg tenure
- 4.1 yr
More centralized structure.
Named executive officers (5)
- David Ricks - CEO since 2017
- Anat Ashkenazi - CFO since 2021
- Daniel Skovronsky - Chief Scientific Officer since 2021
- Anat Hakim - General Counsel since 2020
- Jake Van Naarden - President, Oncology since 2021
Year-over-year changes
R&D leadership expanded and CEO span increased.
- CEO span: 9 → 10
- C-suite size: 9 → 10
- Avg tenure: 4.1 → 3.4 yr
- retitled Daniel Skovronsky - CSPO (was Chief Scientific Officer) (DEF 14A 2025-03-21)
Addition of multiple therapy presidents broadened CEO span.
- CEO span: 10 → 12
- C-suite size: 10 → 12
- Avg tenure: 3.4 → 2.6 yr
- new Carole Ho - President, Neuroscience (DEF 14A 2026-03-20)
Frequently Asked Questions
Who is the CEO of Eli Lilly?
David Ricks has served as Chair, President, and CEO since 2017.
What type of organizational structure does Eli Lilly use?
Lilly uses a divisional structure organized around major therapy areas.
How many direct reports does Eli Lilly's CEO have?
The CEO has 12 direct reports as of 2026.
How has Eli Lilly's leadership changed recently?
In 2025 Lilly appointed new presidents for Neuroscience, Immunology, and Cardiometabolic Health.
Does Eli Lilly have a COO?
No. Lilly operates without a COO, with therapy presidents reporting directly to the CEO.
Sources
- Company filing, 2025
- SEC EDGAR: Eli Lilly and Company DEF 14A Proxy Statement
- SEC EDGAR: Eli Lilly and Company 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Eli Lilly and Company organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/eli-lilly/MLA 9th
"Eli Lilly and Company Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/eli-lilly/. Accessed .Chicago 17
Creately. "Eli Lilly and Company Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/eli-lilly/.Original SEC source View on SEC ↗
Eli Lilly and Company. DEF 14A. Filed 2026-03-20. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/59478/000005947826000029/lly-20260317.htmPermanent URL: https://creately.com/org-chart/fortune-500/eli-lilly/ · last updated 2026-04-01